> ## Content Index
> Fetch the complete content index at: https://www.elenapintea.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pharmacogenomics at the counter: when a patient's genes change the interaction picture
- URL: https://www.elenapintea.com/pharmacogenomics-at-the-counter-when-a-patients-genes-change-the-interaction-picture/
- Published: 2026-10-14T16:34:45.000Z
- Updated: 2026-11-19T16:24:24.000Z
- Description: Most interaction checks look at drug against drug. Pharmacogenomics adds a third factor: the patient's own genes.
- Author: Elena Pintea
- Tags: Drug Interactions

Most interaction checks look at drug against drug. Pharmacogenomics adds a third factor: the patient's own genes. A person who is a poor or ultrarapid metaboliser can experience the equivalent of a strong interaction without taking a second medicine at all.

I studied this in the Pharmacogenomics module of my MSc in Drug Sciences at the University of Basel. As a practising pharmacist, I find it changes how I think about unexpected effects and treatment failures.

### The basic idea

Genetic variants can change three things that matter for drug safety (Relling & Evans, 2015):

- **Metabolism:** enzymes such as CYP2D6, CYP2C19 and CYP2C9 may work faster or slower than usual.
- **Drug targets and transport:** variants can change how a drug reaches or acts on its target.
- **Immune recognition:** certain HLA types make some patients far more likely to develop severe immune-mediated reactions.

A patient who is a CYP2D6 poor metaboliser behaves much like someone taking a strong CYP2D6 inhibitor. When that patient *also* takes an inhibitor, a "drug–drug–gene" interaction can occur.

### Five examples with real clinical consequences

**Codeine and tramadol (CYP2D6).** Both are converted by CYP2D6 into more active opioids. Ultrarapid metabolisers can produce dangerous amounts of morphine from normal doses of codeine (Relling & Evans, 2015). This led European regulators in 2013 to restrict codeine use for pain in children under 12 (European Medicines Agency \[EMA\], 2013). Poor metabolisers, in contrast, may get little pain relief.

**Clopidogrel (CYP2C19).** Clopidogrel is a prodrug activated by CYP2C19\. Poor metabolisers form less active drug and may be less protected against heart attack and stent thrombosis (Relling & Evans, 2015).

**Abacavir (HLA-B\*57:01).** Carriers of this HLA variant have a high risk of a serious hypersensitivity reaction. Screening before treatment is now standard practice and has greatly reduced these reactions (Pavlos et al., 2012).

**Carbamazepine (HLA-B\*15:02).** This variant, more common in people of Han Chinese and Southeast Asian ancestry, is strongly associated with Stevens–Johnson syndrome and toxic epidermal necrolysis (Pavlos et al., 2012).

**Fluoropyrimidines (DPYD).** Patients with reduced DPD enzyme activity are at risk of severe toxicity from 5-fluorouracil and capecitabine. Since 2020, European regulators have recommended testing for DPD deficiency before starting treatment (EMA, 2020).

### The immunosafety connection

The HLA examples link pharmacogenomics directly to immunosafety. In these reactions, the drug or a metabolite interacts with a specific HLA molecule and the immune system treats it as foreign (Pavlos et al., 2012).

This is one reason immune-mediated reactions are hard to predict in clinical trials. They depend on genetic factors present in only a small part of the population. My thesis work on drug-induced immune responses in macrophages gave me a stronger grasp of why these reactions vary so much between individuals.

### What this means at the pharmacy counter

Genetic testing is not routine for most prescriptions. Still, pharmacogenomic thinking improves everyday practice in several ways.

1. **Unexpected effects become a question, not a dead end.** When a patient has severe side effects at a normal dose, or no effect at all, a genetic factor is one possible explanation worth mentioning to the prescriber.
2. **Known results are recorded.** Some patients carry a test result or a card listing their genotype. Recording it in the pharmacy file makes it visible at every future dispensing.
3. **Counselling becomes more specific.** For high-risk drugs such as codeine, I explain which symptoms, such as unusual drowsiness or slow breathing, need immediate attention.
4. **Reports become more informative.** When a suspected adverse reaction is reported and a relevant genotype is known, including it in the report helps reviewers assess the case.

### The industry perspective

Pharmacogenomics runs through the whole life of a medicine. During development, companies study metabolic pathways and may collect DNA samples in clinical trials to explain unusual responses.

After approval, pharmacovigilance can reveal genetic associations, as happened with abacavir and carbamazepine (Pavlos et al., 2012). The result is often an update to the product information, a testing recommendation or a risk minimisation measure.

For safety and regulatory teams, the practical challenge is turning this knowledge into clear, usable guidance for prescribers and pharmacists.

### Why this matters to employers

Pharmacogenomics sits where clinical pharmacology, immunology and drug safety meet. Professionals who understand all three can assess cases more thoroughly, contribute to risk management discussions and communicate complex risks in simple language.

My combination of pharmacy practice, immunopharmacology research and pharmacogenomics training prepares me to do exactly that.

### Key takeaways

- Genes can mimic or amplify drug interactions; the patient is the third factor in every check.
- HLA-associated reactions are a key example of predictable, preventable immune-mediated harm.
- Recording known genotypes and including them in ADR reports improves safety assessment.

### References

European Medicines Agency. (2013, June 28). *Restrictions on use of codeine for pain relief in children: CMDh endorses PRAC recommendation* \[Press release\]. https://www.ema.europa.eu

European Medicines Agency. (2020, April 30). *EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine* \[Press release\]. https://www.ema.europa.eu

Pavlos, R., Mallal, S., & Phillips, E. (2012). HLA and pharmacogenetics of drug hypersensitivity. *Pharmacogenomics, 13*(11), 1285–1306\. https://doi.org/10.2217/pgs.12.108

Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. *Nature, 526*(7573), 343–350\. https://doi.org/10.1038/nature15817